CeriBell (NASDAQ:CBLL) VP Sells $16,205.60 in Stock

CeriBell, Inc. (NASDAQ:CBLL) VP David Foehr sold 862 shares of the firm’s stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $18.80, for a total value of $16,205.60. Following the transaction, the vice president owned 37,751 shares in the company, valued at approximately $709,718.80. This trade represents a 2.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

David Foehr also recently made the following trade(s):

• On Thursday, May 21st, David Foehr sold 987 shares of CeriBell stock. The shares were sold at an average price of $18.00, for a total value of $17,766.00.
• On Tuesday, March 3rd, David Foehr sold 4,560 shares of CeriBell stock. The stock was sold at an average price of $17.80, for a total value of $81,168.00.

CeriBell Stock Down 0.2%

Shares of CeriBell stock opened at $18.67 on Friday. CeriBell, Inc. has a 12-month low of $10.85 and a 12-month high of $24.33. The stock has a market capitalization of $708.34 million, a P/E ratio of -11.45 and a beta of 0.99. The company has a quick ratio of 10.01, a current ratio of 10.44 and a debt-to-equity ratio of 0.14. The stock has a 50 day moving average price of $19.07 and a two-hundred day moving average price of $19.34.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.13). CeriBell had a negative return on equity of 38.19% and a negative net margin of 63.51%.The firm had revenue of $26.49 million during the quarter, compared to analyst estimates of $26.09 million. Equities analysts expect that CeriBell, Inc. will post -1.69 earnings per share for the current year.

Analyst Ratings Changes

CBLL has been the topic of several research analyst reports. Weiss Ratings raised CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday. Canaccord Genuity Group lowered their target price on CeriBell from $28.00 to $25.00 and set a “buy” rating on the stock in a report on Tuesday, May 12th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $22.20.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Strs Ohio acquired a new position in shares of CeriBell during the first quarter valued at about $27,000. Caitong International Asset Management Co. Ltd increased its stake in CeriBell by 3,971.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock valued at $28,000 after acquiring an additional 1,231 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in CeriBell in the 3rd quarter valued at approximately $33,000. CWM LLC lifted its position in shares of CeriBell by 1,178.5% in the 4th quarter. CWM LLC now owns 1,841 shares of the company’s stock worth $40,000 after acquiring an additional 1,697 shares during the period. Finally, Tower Research Capital LLC TRC grew its holdings in shares of CeriBell by 353.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock worth $43,000 after purchasing an additional 1,801 shares in the last quarter.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.